Section 1 Short title
This Act may be cited as the “Childhood Cancer Survivorship, Treatment, Access, and Research Reauthorization Act of 2022” or the “Childhood Cancer STAR Reauthorization Act”.
Childhood Cancer Survivorship, Treatment, Access, and Research Reauthorization Act of 2022
AN ACT
To maximize discovery, and accelerate development and availability, of promising childhood cancer treatments, and for other purposes.
Sec. 2 Reauthorizing and improving the Childhood STAR Act
Children's cancer biorepositories— Section 417E of the Public Health Service Act (42 U.S.C. 285a–11) is amended—
in subsection (a)—
in paragraph (2)(A), by inserting before the period at the end of the second sentence the following: “, such as collected samples of both solid tumor cancer and paired samples”;
in paragraph (9), by striking “Childhood Cancer Survivorship, Treatment, Access, and Research Act of 2018” and inserting “Childhood Cancer Survivorship, Treatment, Access, and Research Reauthorization Act of 2022”;
by redesignating paragraph (10) as paragraph (11); and
by inserting after paragraph (9) the following:
“(10) Report on researcher access to children's cancer biorepository samples—Not later than 2 years after the date of enactment of the Childhood Cancer Survivorship, Treatment, Access, and Research Reauthorization Act of 2022, the Director of NIH shall—
“(A) conduct a review of the procedures established under paragraph (2)(C) and other policies or procedures related to researcher access to such biospecimens to identify any opportunities to reduce administrative burden, consistent with paragraph (2)(D), in a manner that protects personal privacy to the extent required by applicable Federal and State privacy law, at a minimum; and
“(B) submit to the Committee on Health, Education, Labor, and Pensions of the Senate and the Committee on Energy and Commerce of the House of Representatives a report on the findings of the review under subparagraph (A) and whether the Director of NIH plans to make any changes to the policies or procedures considered in such review, based on such findings.”
in subsection (d), by striking “2019 through 2023” and inserting “2024 through 2028”.
Cancer survivorship programs— Section 201 of the Childhood Cancer Survivorship, Treatment, Access, and Research Act of 2018 (Public Law 115–180) is amended—
in subsection (a)—
in the subsection heading, by striking “Pilot programs to explore” and inserting “Research to evaluate”
in paragraph (1)—
by striking “may make awards to eligible entities to establish pilot programs” and inserting “shall, as appropriate, make awards to eligible entities to conduct or support research”;
by striking “model systems” and inserting “approaches”;
by inserting “and adolescent” after “childhood”; and
by striking “evaluation of models for”;
in paragraph (2)—
in subparagraph (A), in the matter preceding clause (i), by inserting “within the existing peer review process,” after “practicable,”; and
in subparagraph (B)(v), by striking “in treating survivors of childhood cancers” and inserting “in carrying out the activities described in paragraph (1)”; and
in paragraph (3)(B)(v), by striking “design of systems for the effective transfer of treatment information and care summaries from cancer care providers to other health care providers” and inserting “design tools to support the secure electronic transfer of treatment information and care summaries between health care providers or, as applicable and appropriate, longitudinal childhood cancer survivorship cohorts”; and
in subsection (b)—
in each of paragraphs (1) and (2), by striking “date of enactment of this Act” and inserting “date of enactment of the Childhood Cancer Survivorship, Treatment, Access, and Research Reauthorization Act of 2022”; and
in paragraph (1)—
by striking subparagraphs (A) and (C);
by redesignating subparagraph (B) as subparagraph (A); and
by adding at the end the following:
“(B) recommendations for enhancing or promoting activities of the Department of Health and Human Services related to workforce development for health care providers who provide psychosocial care to pediatric cancer patients and survivors.”